摘要
CXCL8 是一种与多种神经退行性疾病相关(如阿尔茨海默病与中风)的低分子量中性粒细胞趋化因子。有报道称CXCL8在 HIV-1感染病人的血清、血浆和大脑中表达增加,这表明其与HIV相关的神经性炎症密切相关。因为趋化因子在引起中枢神经系统(CNS)免疫反应时十分关键,而CXCL8作为在大脑中被首次发现的一种趋化因子而显得十分重要。 由HIV-1或病毒相关蛋白激活的星形胶质细胞和小胶质细胞促使脑微环境中趋化因子的生成。因此, CXCL8通过G蛋白偶联受体CXCR1和CXCR2发挥对靶细胞的作用。中性粒细胞是CXCL8的主要靶细胞;本文旨在讨论应对HIV-1感染时,CXCL8在神经元和神经胶质细胞中的产生、信号传导和调节。本文主要关注于CXCL8调节过程中的HIV-1分泌蛋白反转录激活因子、包膜糖蛋白、负调控因子和病毒蛋白r。我们讨论了CXCL8对神经退行性疾病的双重作用和对CNS的神经保护作用。因此,通过CXCR1 /CXCR2为基础的治疗方法,以CXCL8为靶点选择性地激动或拮抗受体,可以选择性促进神经保护作用和增强抗炎效果,这对于中枢神经系统神经炎症包括HIV相关的神经认知障碍的治疗有着重要的临床意义。
关键词: 趋化因子,CXCL8,CXCR1/CXCR2,HIV-1,神经退行性疾病,神经保护作用。
图形摘要
Current Drug Targets
Title:CXCL8 as a Potential Therapeutic Target for HIV-Associated Neurocognitive Disorders
Volume: 17 Issue: 1
Author(s): Manmeet K. Mamik and Anuja Ghorpade
Affiliation:
关键词: 趋化因子,CXCL8,CXCR1/CXCR2,HIV-1,神经退行性疾病,神经保护作用。
摘要: Chemokine CXCL8 is a low molecular weight neutrophil chemoattractant implicated in various neurodegenerative disorders including Alzheimer's disease and stroke. Increased expression of CXCL8 has been reported in serum, plasma and brain of human immunodeficiency virus (HIV)-1 infected individuals with neurocognitive impairment, indicating its role in neuroinflammation associated with HIV-1 infection of the brain. Since chemokines are critical in eliciting immune responses in the central nervous system (CNS), CXCL8 is of particular importance for being one of the first chemokines described in the brain. Activation of astrocytes and microglia by HIV-1 and virus associated proteins results in production of this chemokine in the brain microenvironment. Consequently, CXCL8 exerts its effect on target cells via Gprotein coupled receptors CXCR1 and CXCR2. Neutrophils are the main target cells for CXCL8; however, microglia and neurons also express CXCR1/CXCR2 and therefore are important targets for CXCL8-mediated crosstalk. The objective of this review is to focus on CXCL8 production, signaling and regulation in neuronal and glial cells in response to HIV-1 infection. We highlight the role of HIV-1 secreted proteins such as trans-activator of transcription, envelope glycoprotein, negative regulatory factor and viral protein r in the regulation of CXCL8. We discuss dual role of CXCL8 in neurodegeneration as well as neuroprotection in the CNS. Thus, targeting CXCL8 through the development of CXCR1/CXCR2-based therapeutic strategies to either selectively agonize or antagonize receptors may be able to selectively promote neuroprotective and anti-inflammatory outcomes, leading to significant clinical applications in many neuroinflammatory CNS diseases, including HIV-associated neurocognitive disorders.
Export Options
About this article
Cite this article as:
Manmeet K. Mamik and Anuja Ghorpade , CXCL8 as a Potential Therapeutic Target for HIV-Associated Neurocognitive Disorders, Current Drug Targets 2016; 17 (1) . https://dx.doi.org/10.2174/1389450116666150626124544
DOI https://dx.doi.org/10.2174/1389450116666150626124544 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Methodological Aspects and Applications of In Vivo Imaging of Apoptosis in Oncology: An Illustrative Review
Current Medical Imaging Mechanism of Action of Flavonoids as Anti-inflammatory Agents: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Post-Transcriptional Regulation of HSP70 Expression Following Oxidative Stress in SH-SY5Y Cells: The Potential Involvement of the RNA-Binding Protein HuR
Current Pharmaceutical Design Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Herbal Medicines for the Prevention and Treatment of Alzheimer's Disease
Current Pharmaceutical Design Optimization of Lentiviral Vectors Generation for Biomedical and Clinical Research Purposes: Contemporary Trends in Technology Development and Applications
Current Gene Therapy Pathways of Acetylcholine Synthesis, Transport and Release as Targets for Treatment of Adult-Onset Cognitive Dysfunction
Current Medicinal Chemistry Oxidative Stress in Schizophrenia
Current Neuropharmacology Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Disease Modifying Therapeutic Strategies in Alzheimers Disease Targeting the Amyloid Cascade
Current Neuropharmacology Retinal Degenerations: From Cell Signaling to Cell Therapy; Pre-Clinical and Clinical Issues
Current Gene Therapy 2,5-Diketopiperazines as Neuroprotective Agents
Mini-Reviews in Medicinal Chemistry Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects
Current Medicinal Chemistry Editorial [Hot Topic: Innate Immune Responses in CNS Neurodegenerative Diseases (Guest Editors: Hans van Noort and Sandra Amor)]
CNS & Neurological Disorders - Drug Targets Analysis of Univariate and Multivariate Filters Towards the Early Detection of Dementia
Recent Advances in Computer Science and Communications Flavones from Root of Scutellaria Baicalensis Georgi: Drugs of the Future in Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Non-Demented Individuals with Alzheimer’s Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies
Current Pharmaceutical Design